Journal of Basic and Clinical Physiology and Pharmacology最新文献_第6页

Atrioventricular block and myastenia gravis. A case report and review of the literature. 房室传导阻滞与重症肌无力。病例报告及文献回顾。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-10-01 eCollection Date: 2025-11-01 DOI: 10.1515/jbcpp-2025-0155

Anna Lombardi, Francesco Murru, Luigi Giuseppe Atripaldi, Carmine D'Argenzio, Rita Verdoliva, Giordana G Iannibelli, Claudia Canitano, Mariarosaria De Luca, Giuseppe Cudemo, Rosa Lucci, Andrea Salzano, Alberto M Marra, Michele Arcopinto, Antonio Cittadini

{"title":"Atrioventricular block and myastenia gravis. A case report and review of the literature.","authors":"Anna Lombardi, Francesco Murru, Luigi Giuseppe Atripaldi, Carmine D'Argenzio, Rita Verdoliva, Giordana G Iannibelli, Claudia Canitano, Mariarosaria De Luca, Giuseppe Cudemo, Rosa Lucci, Andrea Salzano, Alberto M Marra, Michele Arcopinto, Antonio Cittadini","doi":"10.1515/jbcpp-2025-0155","DOIUrl":"10.1515/jbcpp-2025-0155","url":null,"abstract":"Objectives: Myasthenia gravis (MG) is a chronic autoimmune disease primarily affecting skeletal muscles, though cardiac involvement, particularly arrhythmias, may occur, especially in severe cases or in patients with thymoma.Case presentation: We report the case of a 62-year-old male with AchR-Ab-positive MG, without thymoma, who developed an advanced atrioventricular block requiring pacemaker implantation. Cardiac manifestations in MG can result from either the disease itself - through myocarditis, autoantibodies and autonomic dysfunction - or as a side effect of treatments such as pyridostigmine and immunosuppressants. Management strategies include considering discontinuation of pyridostigmine or using hyoscyamine to assess potential drug-induced bradyarrhythmias before proceeding with permanent pacing.Conclusions: This case highlights the diagnostic challenges in distinguishing iatrogenic from autoimmune cardiac complications and emphasizes the importance of cardiovascular monitoring in MG patients, especially those presenting with cardiac symptoms or EKG abnormalities. Early recognition and appropriate intervention are crucial to improve outcomes and quality of life.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"383-387"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mental toughness and athletic performance: a narrative review. 心理韧性与运动表现：一种叙事回顾。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-09-25 eCollection Date: 2026-01-01 DOI: 10.1515/jbcpp-2025-0091

Raja Soundara Pandian Pachaiappan, Veera Balajikumar Veeraswamy, Kannan Mahalingam, Gurubharathy Gurusamy, Bijulakshmi Parthiban

{"title":"Mental toughness and athletic performance: a narrative review.","authors":"Raja Soundara Pandian Pachaiappan, Veera Balajikumar Veeraswamy, Kannan Mahalingam, Gurubharathy Gurusamy, Bijulakshmi Parthiban","doi":"10.1515/jbcpp-2025-0091","DOIUrl":"10.1515/jbcpp-2025-0091","url":null,"abstract":"Background: Mental toughness represents a crucial psychological construct in competitive sports. This narrative review examines the relationship between mental toughness and athletic performance across various sports domains.Methods: We conducted a comprehensive literature review of empirical studies published between 2000 and 2024. Relevant articles were identified through database searches including PubMed, PsycINFO, SPORTDiscus, and Web of Science. Studies examining mental toughness in relation to performance outcomes in competitive athletes were included.Results: Evidence consistently shows positive correlations between mental toughness and athletic performance (r=0.21-0.63). Mental toughness demonstrates stronger associations with performance in individual sports compared to team sports. Additionally, psychological interventions targeting mental toughness components show promise for enhancing athletic outcomes.Conclusions: Mental toughness represents a significant psychological factor in athletic achievement. The construct influences performance through multiple pathways including resilience to pressure, emotional regulation, and focus maintenance. Practical applications for coaches and sport psychologists are discussed.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of polypharmacy and appropriateness of prescription in geriatric patients using Beer's criteria at tertiary care hospital: a record based retrospective study. 利用Beer标准评价三级医院老年患者的多药及处方适宜性：一项基于记录的回顾性研究。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-09-18 eCollection Date: 2025-11-01 DOI: 10.1515/jbcpp-2024-0099

Geetanjali Hiremath, Radhika Sherkhane, Shrikant Hiremath

{"title":"Evaluation of polypharmacy and appropriateness of prescription in geriatric patients using Beer's criteria at tertiary care hospital: a record based retrospective study.","authors":"Geetanjali Hiremath, Radhika Sherkhane, Shrikant Hiremath","doi":"10.1515/jbcpp-2024-0099","DOIUrl":"10.1515/jbcpp-2024-0099","url":null,"abstract":"Objectives: The current study aims to evaluate the aptness of prescription in elderly along with looking out for polypharmacy, overprescribing and under prescribing in geriatric patients being treated at the tertiary care hospital.Methods: This is a retrospective record-based study, data was collected from 1st January 2017 to 31st December 2018 of all the patient which are falling in the inclusion criteria. Prescription appropriateness was assessed implementing 'Beers criteria'. Errors in prescription along with administration were checked by direct observation and analysis of prescriptions.Results: Out of total 2,718 patients, 58.6 % were found to be males and 41.4 % were females. Most common comorbidities found were hypertension and coronary artery diseases (CAD). In the current study, 39 % of the prescription contained inappropriate medication and 11.20 % prescriptions were having adverse drug reaction. Error by attending nurse in prescription reading came out to be the most common error in this study.Conclusions: Diclofenac was found to be the most commonly used inappropriate drug as per Beer's criteria. Clinicians should be more cautious when using drugs in old age patients.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"359-363"},"PeriodicalIF":0.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A cross-sectional observational study of the prevalence and characterization of potential QT-prolonging drug‒drug interactions in oncological outpatients. 肿瘤门诊患者中潜在延长qt的药物-药物相互作用的患病率和特征的横断面观察研究。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-08-12 eCollection Date: 2025-11-01 DOI: 10.1515/jbcpp-2024-0104

Akash Agnihotri, Biswadeep Das, Sachin Manocha, Manjunath Bidarolli, Bharati Vashisht

{"title":"A cross-sectional observational study of the prevalence and characterization of potential QT-prolonging drug‒drug interactions in oncological outpatients.","authors":"Akash Agnihotri, Biswadeep Das, Sachin Manocha, Manjunath Bidarolli, Bharati Vashisht","doi":"10.1515/jbcpp-2024-0104","DOIUrl":"10.1515/jbcpp-2024-0104","url":null,"abstract":"Objectives: This study aims to assess the prevalence, characteristics, and risk factors of potential QT-prolonging drug-drug interactions (pQT-DDIs) in cancer patients, including identifying drug combinations contributing to QT prolongation and key predictors.Methods: In this hospital-based, cross-sectional observational study, all types of cancer patients, irrespective of age or sex, were included over 1 year. pQT-DDIs were identified using four drug interaction checker software tools. Predictors were analyzed using univariate logistic regression.Results: A total of 1,331 cancer patients were included. The prevalence of pQT-DDIs was 67.6 %. Of these, 606 (45.5 %) had 1-2 pQT-DDIs, 126 (9.5 %) had 3-4, and 78 (5.9 %) had 5-6. Overall, 163 drug combinations were identified as causing QT prolongation; 122 were detected by Drugs.com. Significant predictors included >8 drugs prescribed (OR=6.46; CI=4.87-8.56; p<0.0001), >2 anticancer drugs (OR=1.68; CI=1.14-2.46; p=0.008), >6 adjuvant drugs (OR=6.83; CI=5.17-9.03; p<0.0001), solid cancers (OR=6.59; CI=4.59-8.80; p<0.0001), and cytotoxic drug use (OR=2.40; CI=1.52-3.77; p=0.0001).Conclusions: There is a high prevalence of pQT-DDIs in cancer patients. Those receiving multiple anticancer and adjuvant drugs are at higher risk. Routine interaction screening is recommended before chemotherapy.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"373-381"},"PeriodicalIF":0.0,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis. 西拉得帕：对其治疗原发性胆管炎的临床疗效和安全性的综合评价。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-08-11 eCollection Date: 2025-09-01 DOI: 10.1515/jbcpp-2024-0124

Ajay Kumar Shukla, Saurav Misra

{"title":"Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis.","authors":"Ajay Kumar Shukla, Saurav Misra","doi":"10.1515/jbcpp-2024-0124","DOIUrl":"10.1515/jbcpp-2024-0124","url":null,"abstract":"Primary biliary cholangitis (PBC) is a chronic liver disease leading to liver damage and potentially death. The first-line treatment is ursodeoxycholic acid (UDCA), but some patients do not respond well. Obeticholic acid (OCA) is a second-line treatment option. Fenofibrate (a predominantly PPAR-α agonist) and bezafibrate (a pan-PPAR agonist) are currently used in clinical practice as anticholestatic agents to improve serum biochemistry in PBC. Seladelpar, a peroxisome proliferator-activated receptor-delta (PPARδ) agonist, has demonstrated potent anti-cholestatic effects in clinical studies. The aim of this analysis was to summarise the data available on efficacy and safety of seladelpar for the treatment of primary biliary cholangitis (PBC). We conducted a search in PubMed, Embase and Web of Science for studies on seladelpar until June 1, 2024. The analysis included review articles, randomized controlled trials, cohort studies and case-control studies. Seladelpar is a once daily oral, potent and selective PPAR-δ agonist. Activation of PPAR-δ on hepatocytes and cholangiocytes improves cholestasis by downregulating the rate-limiting enzyme, CYP 7A1, used for bile synthesis, as well as reducing cholesterol synthesis and dietary absorption, leading to a reduction in bile acid pools. In this review, we have summarised the preclinical and clinical data on seladelpar. There is a need for additional phase III studies to provide sufficient clinical evidence for the efficacy and safety of this investigational drug, as current evidence is limited to phase III studies and does not yet prove its worth in a larger population.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"331-337"},"PeriodicalIF":0.0,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive review on superficial mycoses, classification, conventional/new therapeutic approaches and fungal-drug resistance. 浅表真菌病，分类，传统/新治疗方法和真菌耐药性的综合综述。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-08-04 eCollection Date: 2025-09-01 DOI: 10.1515/jbcpp-2024-0010

Noor Ul Islam, Muhammad Ikram, Muhammad Zahoor, Riaz Ullah

引用次数: 0

Study on the molecular aspect of cardioprotective effects of selenium: a mini-review. 硒对心脏保护作用的分子机制研究综述。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-08-01 eCollection Date: 2025-09-01 DOI: 10.1515/jbcpp-2024-0128

Neda Roshanravan, Samad Ghaffari, Majid Mosharkesh, Rezayat Parvizi, Shamsi Ghaffari, Erfan Mosharkesh, Ahmad Separham

引用次数: 0

The current pathogenicity and potential risk evaluation of Ebola virus to cause mysterious disease X - An update on recent evidences. 目前埃博拉病毒引起神秘疾病X的致病性和潜在风险评价——最新证据。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-07-22 eCollection Date: 2025-11-01 DOI: 10.1515/jbcpp-2023-0240

Abir Hasan Pranto, Md Rabiul Islam

引用次数: 0

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. 利特鲁肽治疗肥胖的有效性和安全性：临床试验的系统回顾。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-07-21 eCollection Date: 2025-07-01 DOI: 10.1515/jbcpp-2025-0113

Saurav Misra, Ravi Kant Narayan, Manmeet Kaur

{"title":"Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.","authors":"Saurav Misra, Ravi Kant Narayan, Manmeet Kaur","doi":"10.1515/jbcpp-2025-0113","DOIUrl":"10.1515/jbcpp-2025-0113","url":null,"abstract":"Introduction: Obesity is a major public health issue linked to various health complications. Retatrutide, a triple agonist peptide targeting the glucagon receptor, GIP receptor, and GLP-1 receptor, shows promise in addressing this need.Content: This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data. We conducted a comprehensive search of databases, including PubMed, Cochrane and ClinicalTrials.gov, from their inception until March 15, 2025 following PRISMA guidelines.Summary: Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups. The average age of participants was 54.26 ± 9.9 years, consisting of 335 men (48 %) and 356 women (52 %). Retatrutide was administered to 510 participants, while 130 received a placebo. The 12 mg dosage of retatrutide showed the most significant reductions in body weight, body mass index, and waist circumference. It also led to a higher percentage of patients achieving weight losses of ≥5 , 10, 15, and 20 %. Gastrointestinal adverse effects were the most commonly reported.Outlook: Weekly subcutaneous injections of retatrutide in obese patients resulted in significant weight loss and metabolic improvements compared to a placebo.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"36 4","pages":"263-274"},"PeriodicalIF":0.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physiological belching during impedance-pH monitoring: a meal with Coca-Cola provokes a prompt gastroesophageal reaction with increased prandial belching. 阻抗- ph监测期间的生理性打嗝：一顿可口可乐餐会引起胃食管反应，增加餐后打嗝。

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-07-21 eCollection Date: 2026-01-01 DOI: 10.1515/jbcpp-2024-0050

Alessandra B Melchior, Martina E Da Cas, Nicolle Surkamp, Victória Zamprogna, Matheus P Silveira, Tarcisio S Santos, Lucas Z Montenegro, Luiza M Volpi, Fernando Fornari

{"title":"Physiological belching during impedance-pH monitoring: a meal with Coca-Cola provokes a prompt gastroesophageal reaction with increased prandial belching.","authors":"Alessandra B Melchior, Martina E Da Cas, Nicolle Surkamp, Victória Zamprogna, Matheus P Silveira, Tarcisio S Santos, Lucas Z Montenegro, Luiza M Volpi, Fernando Fornari","doi":"10.1515/jbcpp-2024-0050","DOIUrl":"10.1515/jbcpp-2024-0050","url":null,"abstract":"Objectives: To assess the belching-related esophageal events in healthy volunteers during and after fast-food meals.Methods: Ten adult healthy volunteers had two lunches with a Big Mac® on different days, accompanied or not by Coca-Cola (500 mL, pH<3) in a random way. We assessed prandial and 2 h postprandial esophageal events using impedance-pH monitoring.Results: During meals with Coca-Cola, most signed belching (68 %) were concomitant with prolonged esophageal acidification or acid reflux, and the belching number was superior [median: 9.5 (IQR 4.7-14) vs. 0 (0-3); p=0.002] and less frequently represented by pure gas (24 % vs. 92 %; p<0.001) than in meals without Coca-Cola. Postprandial belching did not differ either in frequency [median: 15.5 (6-20.2) vs. 13.5 (10.7-20.5); p=0.739] or in type [(median %) pure gas: 6.7 % vs. 11.7 %; during acid reflux: 64.6 % vs. 51.7 %; during nonacid reflux: 22.5 % vs. 22.2 %; p=0.300), with more than 80 % of belching coincident with asymptomatic liquid reflux, regardless of Coca-Cola intake. Postprandial gastroesophageal reflux and esophageal acid exposure were similar, irrespective of Coca-Cola intake.Conclusions: In healthy volunteers, a fast-food meal with Coca-Cola provoked a prompt reaction with increased prandial belching and esophageal acidification. Coca-Cola did not change postprandial belching, often accompanied by silent gastroesophageal liquid reflux.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"37 1","pages":"63-69"},"PeriodicalIF":0.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146085885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0